All In Biotech

Drug Trial Radar · NCT06132256

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 145 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

145

Actual

Start

Dec 11, 2023

Primary completion

Aug 27, 2026

Study completion Sep 10, 2026

Sponsor

Lead sponsor
Syndax PharmaceuticalsIndustry
Sponsor type
Industry
Collaborators
DevPro Biopharma
First posted
Nov 15, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will evaluate the efficacy and safety of axatilimab in participants with IPF.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • AxatilimabDrug

    Administered as intravenous (IV) infusion

  • PlaceboOther

    Placebo to match axatilimab administered as IV infusion. Placebo will not contain active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized rate of decline in morning pre-dose trough forced vital capacity (FVC) (milliliter [mL])Time frame: Baseline through Week 26

Locations

78 sites in 13 countries. Site status is shown where the registry gives one.

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • Sunshine Coast University Hospital

    Birtinya, Queensland, Australia

  • Wallace Street Specialist Centre

    Brisbane, Queensland, Australia

  • Mater Misericordiae Ltd

    South Brisbane, Queensland, Australia

  • Griffith University Clinical Trial Unit

    Southport, Queensland, Australia

  • Mackay Hospital & Health Service

    West Mackay, Queensland, Australia

  • Monash Health

    Clayton, Victoria, Australia

  • Institute for Respiratory Health

    Perth, Western Australia, Australia

  • OLV Hospital Aalst

    Aalst, Oost-Vlaanderen, Belgium

  • AZ Groeninge

    Kortrijk, West-Vlaanderen, Belgium

  • Dynamic Drug Advancement

    Ajax, Canada

  • Centre de Recherche Clinique - CHUS

    Sherbrooke, Quebec, Canada

  • Thomayer University Hospital

    Prague, Czechia

  • CHU Amiens

    Amiens, France

  • Chu Brest

    Brest, France

  • CHU Dijon

    Dijon, France

  • CHU de Rennes

    Rennes, France

  • Klinikum Chemnitz - Zentrum für klinische Studien

    Chemnitz, Germany

  • Studienzentrum Dr. Keller

    Frankfurt am Main, Germany

  • Asklepios Lungenklinik Gauting

    Gauting, Germany

  • RoMed Klinikum Rosenheim

    Rosenheim, Germany

  • Klinikum Konstanz, Innere Medizin, Pneumologie

    Konstanz, Baden-Wurttemberg, Germany

  • Pneumologisches Studienzentrum München-West

    Munich, Bavaria, Germany

  • Medizinische Hochschule Hannover

    Hanover, Lower Saxony, Germany

  • A.O.U. Policlinico "G. Rodolico - San Marco"

    Catania, Italy

  • Azienda Ospedaliero Universitaria di Careggi

    Florence, Italy

  • AOU di Modena

    Modena, Italy

  • AOU Città della Salute e della Scienza di Torino - Molinette

    Molinette, Italy

  • ISMETT

    Palermo, Italy

  • Ospedale Colonnello D'Avanzo

    Foggia, Apulia, Italy

  • ASST Santi Paolo e Carlo

    Milan, Lombardy, Italy

  • San Gerardo

    Monza, MB, Italy

  • Azienda Ospedaliera Universitaria San Luigi Gonzaga

    Torino, Orbassano, Italy

  • University of Padua

    Padova, Padua, Italy

  • Azienda Ospedaliera Universitaria Senese

    Siena, Tuscany, Italy

  • Mics Centrum Medyczne Bydgoszcz

    Bydgoszcz, Poland

  • Makowskie Centrum medyczne Hamernia Sp zz

    Maków Podhalański, Poland

  • Warmia and Mazury Center for Lung Diseases

    Olsztyn, Poland

  • Vitamed Galaj I Cichomski sp.j.

    Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland

  • Clinica Lavinia Davidescu SRL

    Oradea, Romania

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.